{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-007198","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.719584+00:00","generated_at":"2026-05-27T06:44:02.053421+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunome launches public offering of common stock; pipeline update with Phase 3 data H2 2025","bullets":["Underwritten public offering of common stock commenced; size not disclosed.","Preliminary cash, equivalents and marketable securities $217.3M as of Dec 31, 2024.","Varegacestat Phase 3 desmoid tumor trial fully enrolled; topline data expected H2 2025.","IM-1021 (ROR1 ADC) IND cleared Dec 2024; Phase 1 starts Q1 2025 at 2 mg/kg starting dose.","IM-3050 (FAP RLT) IND submission expected Q1 2025; three ADCs in IND-enabling manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-007198","json":"https://secwatch.observer/filing/0001104659-25-007198.json","markdown":"https://secwatch.observer/filing/0001104659-25-007198.md","text":"https://secwatch.observer/filing/0001104659-25-007198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465925007198/0001104659-25-007198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465925007198/tm254675d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T06:44:02.053421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}